BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 20587907)

  • 1. Role of Ki-67 as a proliferative marker in lesions of thyroid.
    Pujani M; Arora B; Pujani M; Singh SK; Tejwani N
    Indian J Cancer; 2010; 47(3):304-7. PubMed ID: 20587907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors.
    Erickson LA; Jin L; Wollan PC; Thompson GB; van Heerden J; Lloyd RV
    Mod Pathol; 1998 Feb; 11(2):169-74. PubMed ID: 9504687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of MIB-1 immunoreactivity and nucleolar organizer regions in nonneoplastic and neoplastic thyroid lesions.
    Lewy-Trenda I; Bieńkiewicz M
    Pol J Pathol; 1999; 50(3):129-38. PubMed ID: 10624114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms.
    Aron M; Kapila K; Verma K
    Indian J Pathol Microbiol; 2006 Jul; 49(3):376-80. PubMed ID: 17001889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of a combination of Ki-67, Galectin-3, and PTTG can distinguish the benign and malignant thyroid tumor.
    Cui W; Lu X; Zheng S; Ma Y; Liu X; Zhang W
    Clin Lab; 2012; 58(5-6):419-26. PubMed ID: 22783570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of cyclin D1 gene expression as a prognostic factor in benign and malignant thyroid lesions.
    Brzeziańska E; Cyniak-Magierska A; Sporny S; Pastuszak-Lewandoska D; Lewiński A
    Neuro Endocrinol Lett; 2007 Aug; 28(4):341-50. PubMed ID: 17693985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of AgNORs and ki-67 proliferative markers in differential diagnosis of thyroid lesions.
    Aiad HA; Bashandy MA; Abdou AG; Zahran AA
    Pathol Oncol Res; 2013 Apr; 19(2):167-75. PubMed ID: 23055017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of fine needle aspiration of the thyroid in an endemic goiter region.
    Harach HR
    Acta Cytol; 1989; 33(1):31-5. PubMed ID: 2916369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of the thyroid peroxidase marker for distinguishing follicular thyroid carcinoma from follicular adenoma.
    Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
    Exp Oncol; 2006 Mar; 28(1):70-4. PubMed ID: 16614712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.
    Than TH; Swethadri GK; Wong J; Ahmad T; Jamil D; Maganlal RK; Hamdi MM; Abdullah MS
    Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms.
    Mehrotra P; Okpokam A; Bouhaidar R; Johnson SJ; Wilson JA; Davies BR; Lennard TW
    Histopathology; 2004 Nov; 45(5):493-500. PubMed ID: 15500653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?
    Pu RT; Yang J; Wasserman PG; Bhuiya T; Griffith KA; Michael CW
    Diagn Cytopathol; 2006 May; 34(5):330-4. PubMed ID: 16604553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minichromosome maintenance protein 3 is a candidate proliferation marker in papillary thyroid carcinoma.
    Lee YS; Ha SA; Kim HJ; Shin SM; Kim HK; Kim S; Kang CS; Lee KY; Hong OK; Lee SH; Kwon HS; Cha BY; Kim JW
    Exp Mol Pathol; 2010 Feb; 88(1):138-42. PubMed ID: 19818763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fine-needle aspiration biopsy of Hurthle cell lesions of the thyroid gland: A cytomorphologic study of 139 cases with statistical analysis.
    Elliott DD; Pitman MB; Bloom L; Faquin WC
    Cancer; 2006 Apr; 108(2):102-9. PubMed ID: 16453320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detection of cytokeratin 19 and thyroperoxidase expressions in the diagnosis of thyroid diseases].
    Yang QX; Shao CK; Feng ZY; Huang BQ; Han AJ; Xiong M; Zhao WL; Wu TT
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):678-81. PubMed ID: 15958307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcription factor-mediated proliferation and apoptosis in benign and malignant thyroid lesions.
    Letsas KP; Frangou-Lazaridis M; Skyrlas A; Tsatsoulis A; Malamou-Mitsi V
    Pathol Int; 2005 Nov; 55(11):694-702. PubMed ID: 16271081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A comparative study of cytological and histological studies of the thyroid gland].
    Emmrich P; Gauer G; Gauer J; Mättig H; Rosenkranz M
    Zentralbl Chir; 2001 Apr; 126(4):267-72. PubMed ID: 11370387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of cytokeratin-19, galectin-3, and Hector Battifora mesothelial-1 in the diagnosis of benign and malignant thyroid nodules.
    Cui W; Sang W; Zheng S; Ma Y; Liu X; Zhang W
    Clin Lab; 2012; 58(7-8):673-80. PubMed ID: 22997967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ki-67 as proliferative marker of thyroid.
    Wiwanitkit V
    Indian J Cancer; 2011; 48(3):378. PubMed ID: 21921351
    [No Abstract]   [Full Text] [Related]  

  • 20. In situ detection of hTERT mRNA relates to Ki-67 labeling index in papillary thyroid carcinoma.
    Chou SJ; Chen CM; Harn HJ; Chen CJ; Liu YC
    J Surg Res; 2001 Jul; 99(1):75-83. PubMed ID: 11421607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.